Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.
Anniversary Issue on Gene and Cell Therapy 2014Latest Articles
- FDA Names Prasad CBER Director, Sparking Gene Therapy Review Concerns
- Progress Toward a Cure for All Patients with Cystic Fibrosis: An Interview with Patrick Thibodeau, PhD
- Hepatocyte Growth Factor-Modified Dental Pulp Stem Cells Potentially Regulate Novel Renal Fibrosis-Associated Gene via PI3K/AKT/GSK3β Pathway to Alleviate Renal Fibrosis
- Stromal Gene Therapy Mediates Prolonged Protection Against Corneal Neovascularization Induced by an Aggressive Angiogenic Insult
- Novel Cystic Fibrosis Ferret Model Enables Visualization of CFTR Expression Cells and Genetic CFTR Reactivation